FDA adds new safety information to statin drugs

February 28, 2012

(AP) -- Federal health officials are adding new safety warnings about risks of memory loss and elevated blood sugar to statins, a widely prescribed group of cholesterol-lowering medications.

The Food and Drug Administration announced several labeling changes to medicines like Lipitor, Crestor and Zocor.

Labeling on all such drugs will warn of memory loss and confusion reported among certain patients taking statins. The problems were generally not serious and went away after patients stopped taking the drugs, according to the FDA.

The updated labels will also mention elevated levels of blood sugar reported in some patients taking statins.

Statins are mainly prescribed to prevent heart attacks in people with and work by dramatically lowering LDL or "." They were the third best-selling drug class in the U.S. for 2010.

Explore further: Stopping statins after stroke raises risk of death, dependency

shares

Related Stories

FDA confirms benefits of Crestor in more patients

December 11, 2009

(AP) -- Federal scientists say AstraZeneca's cholesterol pill Crestor lowers the risk of heart attack, death and stroke in patients without a history of heart disease, though some safety concerns remain.

Recommended for you

Non-addictive painkiller shows promise in animal trials

August 30, 2016

(HealthDay)—Preliminary research in monkeys suggests that a new medication might be able to provide pain relief similar to opioid drugs such as OxyContin, but without the same potential for addiction or serious side effects.

Mylan launching cheaper, generic version of EpiPen

August 29, 2016

The maker of EpiPens will start selling a cheaper, generic version of the emergency allergy shots as the furor over repeated U.S. price hikes continues—and looming competition threatens its near-monopoly.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.